

United States Senate  
WASHINGTON, DC 20510

September 21, 2015

The Honorable Mitch McConnell  
United States Senate  
Washington, DC 20510

The Honorable Harry Reid  
United States Senate  
Washington, DC 20510

Dear Majority Leader McConnell and Minority Leader Reid:

As sponsors and cosponsors of S. 275, the Medicare Home Infusion Site of Care Act, we write to urge that any savings that result from changing reimbursement of Medicare Part B Durable Medical Equipment (DME) infusion drugs be associated with the passage of a comprehensive Medicare home infusion benefit. The U.S. House of Representatives has passed legislation (H.R. 6, H.R. 2570) to change Medicare reimbursement of Part B DME infusion drugs to an Average Sales Price (ASP) methodology. Unfortunately, without the inclusion of payment for required professional services for home infusion providers, these changes leave thousands of patients at risk of losing access to vital care.

Currently, Medicare covers infusion therapy in hospitals, nursing homes, and physician office settings. Reimbursement for infusion therapy in the home will allow patients to fully recover at home, which lowers the risk of healthcare-associated infections, while also saving money for the Medicare program. We believe this concept is a step in the right direction and that any disruption in efforts to establish Medicare coverage for home infusion therapy would be to the detriment of patients.

As we continue to work toward a Medicare program that reflects the current needs of older and disabled Americans, it is important that we take an inclusive approach to home infusion coverage and payment. We urge that the ASP pricing provisions from H.R. 6 or H.R. 2570 not be included in any legislation that does not recognize the services component of care that is included in S. 275. We respectfully request that we have adequate time to review S. 275 with CMS and to address home infusion therapy in a manner that does not compromise access to care for Medicare beneficiaries in need of this critical benefit.

Should you have questions for us, please feel free to contact Jordan Bartolomeo (Senator Isakson) at extension 8-5441, or Marvin Figueroa (Senator Warner) at extension 4-2023. Thank you for considering our concerns on this pressing issue.

Sincerely,



Johnny Isakson  
United States Senator



Mark R. Warner  
United States Senator



Kelly A. Ayotte  
United States Senator



Michael F. Bennet  
United States Senator



Richard Burr  
United States Senator



Thad Cochran  
United States Senator




Kirsten E. Gillibrand  
United States Senator




Chuck Grassley  
United States Senator




Amy Klobuchar  
United States Senator



James Lankford  
United States Senator



Jerry Moran  
United States Senator



Pat Roberts  
United States Senator



Jeanne Shaheen  
United States Senator

CC: Chairman Orrin Hatch, Senate Finance Committee  
Ranking Member Ron Wyden, Senate Finance Committee